ProShare Advisors’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $303K | Sell |
3,936
-584
| -13% | -$45.6K | ﹤0.01% | 1334 |
|
|
2025
Q4 | $357K | Buy |
4,520
+336
| +8% | +$29.1K | ﹤0.01% | 1349 |
|
|
2025
Q3 | $383K | Sell |
4,184
-662
| -14% | -$54K | ﹤0.01% | 1259 |
|
|
2025
Q2 | $316K | Sell |
4,846
-454
| -9% | -$29.6K | ﹤0.01% | 1406 |
|
|
2025
Q1 | $355K | Sell |
5,300
-1,232
| -19% | -$73.6K | ﹤0.01% | 1298 |
|
|
2024
Q4 | $361K | Buy |
6,532
+1,469
| +29% | +$84.3K | ﹤0.01% | 1486 |
|
|
2024
Q3 | $302K | Buy |
5,063
+1,493
| +42% | +$91.1K | ﹤0.01% | 1457 |
|
|
2024
Q2 | $227K | Sell |
3,570
-877
| -20% | -$56.9K | ﹤0.01% | 1465 |
|
|
2024
Q1 | $307K | Buy |
4,447
+404
| +10% | +$24.4K | ﹤0.01% | 1417 |
|
|
2023
Q4 | $223K | Buy |
4,043
+472
| +13% | +$26K | ﹤0.01% | 1578 |
|
|
2023
Q3 | $207K | Buy |
+3,571
| New | +$206K | ﹤0.01% | 1442 |
|
|
2020
Q1 | – | Sell |
-4,106
| Closed | -$253K | – | 1188 |
|
|
2019
Q4 | $253K | Sell |
4,106
-442
| -10% | -$29.3K | ﹤0.01% | 1442 |
|
|
2019
Q3 | $331K | Sell |
4,548
-50
| -1% | -$3.74K | ﹤0.01% | 1173 |
|
|
2019
Q2 | $378K | Sell |
4,598
-534
| -10% | -$38K | ﹤0.01% | 1129 |
|
|
2019
Q1 | $362K | Buy |
5,132
+39
| +0.8% | +$2.29K | ﹤0.01% | 1164 |
|
|
2018
Q4 | $229K | Sell |
5,093
-914
| -15% | -$47.9K | ﹤0.01% | 1297 |
|
|
2018
Q3 | $340K | Sell |
6,007
-293
| -5% | -$17.9K | ﹤0.01% | 1285 |
|
|
2018
Q2 | $421K | Sell |
6,300
-389
| -6% | -$24.3K | ﹤0.01% | 1204 |
|
|
2018
Q1 | $389K | Sell |
6,689
-1,044
| -14% | -$66.3K | ﹤0.01% | 1202 |
|
|
2017
Q4 | $498K | Buy |
7,733
+453
| +6% | +$28.2K | ﹤0.01% | 1135 |
|
|
2017
Q3 | $382K | Buy |
7,280
+479
| +7% | +$22.8K | ﹤0.01% | 1059 |
|
|
2017
Q2 | $318K | Sell |
6,801
-477
| -7% | -$23K | ﹤0.01% | 1133 |
|
|
2017
Q1 | $360K | Sell |
7,278
-1,822
| -20% | -$102K | ﹤0.01% | 1159 |
|
|
2016
Q4 | $552K | Buy |
9,100
+897
| +11% | +$54.8K | 0.01% | 1032 |
|
|
2016
Q3 | $544K | Sell |
8,203
-1,489
| -15% | -$93.1K | 0.01% | 923 |
|
|
2016
Q2 | $541K | Buy |
9,692
+81
| +0.8% | +$3.94K | 0.01% | 934 |
|
|
2016
Q1 | $324K | Sell |
9,611
-962
| -9% | -$32.6K | ﹤0.01% | 1175 |
|
|
2015
Q4 | $477K | Buy |
10,573
+946
| +10% | +$40.7K | 0.01% | 1054 |
|
|
2015
Q3 | $380K | Sell |
9,627
-636
| -6% | -$36.2K | 0.01% | 1032 |
|
|
2015
Q2 | $637K | Sell |
10,263
-462
| -4% | -$27.5K | 0.01% | 988 |
|
|
2015
Q1 | $671K | Buy |
10,725
+1,752
| +20% | +$107K | 0.01% | 1039 |
|
|
2014
Q4 | $506K | Buy |
+8,973
| New | +$396K | 0.01% | 1192 |
|
Other funds holding ANIP
VCM
SCM
TCM
GAM
DTC
ProShare Advisors's ANIP Position: Q1 2026 in Review
ProShare Advisors reduced its ANI Pharmaceuticals (ANIP) stake by 13% in Q1 2026, selling an estimated $45.6K and leaving 3,936 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #1334.
ProShare Advisors first reported a position in ANIP in Q4 2014 and has held it in 32 quarters since. The position peaked at $671K in Q1 2015. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.
- ProShare Advisors held 3,936 shares of ANI Pharmaceuticals worth $303K as of Q1 2026.
- ProShare Advisors sold 584 ANI Pharmaceuticals shares in Q1 2026, an estimated $45.6K.
- ANI Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1334 holding.
- ProShare Advisors first reported a position in ANI Pharmaceuticals in Q4 2014 and has held it in 32 quarters since.
- ProShare Advisors's ANI Pharmaceuticals position peaked at $671K in Q1 2015.
- 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.